Literature DB >> 24934908

Venom immunotherapy: an updated review.

Darío Antolín-Amérigo1, Carmen Moreno Aguilar, Arantza Vega, Melchor Alvarez-Mon.   

Abstract

Venom immunotherapy (VIT) is the most effective form of specific immunotherapy to date. Hitherto, several relevant queries remain unanswered, namely optimal doses, duration, and means of assessment. Important progress has been lately made in terms of diagnosis by means of component-resolved diagnosis. Moreover, basophil activation test results in patients with negative serum immunoglobulin E (IgE) and skin prick test confer this technique a promising future, although these outcomes shall be considered with caution. This review aims to unravel the important advances made on diagnosis, management, and prognosis and also focuses on several undetermined aspects of VIT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24934908     DOI: 10.1007/s11882-014-0449-1

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  73 in total

1.  Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.

Authors:  Franziska Ruëff; Bernhard Przybilla; Maria Beatrice Biló; Ulrich Müller; Fabian Scheipl; Werner Aberer; Joëlle Birnbaum; Anna Bodzenta-Lukaszyk; Floriano Bonifazi; Christoph Bucher; Paolo Campi; Ulf Darsow; Cornelia Egger; Gabrielle Haeberli; Thomas Hawranek; Iwona Kucharewicz; Helmut Küchenhoff; Roland Lang; Oliviero Quercia; Norbert Reider; Maurizio Severino; Michael Sticherling; Gunter Johannes Sturm; Brunello Wüthrich
Journal:  J Allergy Clin Immunol       Date:  2010-06-12       Impact factor: 10.793

2.  Monitoring honeybee venom immunotherapy in children with the basophil activation test.

Authors:  Simona E K Žitnik; Tina Vesel; Tadej Avčin; Mira Šilar; Mitja Košnik; Peter Korošec
Journal:  Pediatr Allergy Immunol       Date:  2011-12-04       Impact factor: 6.377

3.  Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy.

Authors:  Joanne N G Oude Elberink; Jan G R de Monchy; David B k Golden; Jan-Leendert P Brouwer; Gordon H Guyatt; Anthony E J Dubois
Journal:  J Allergy Clin Immunol       Date:  2002-01       Impact factor: 10.793

4.  Early markers for protective mechanisms during rush venom immunotherapy.

Authors:  C Bussmann; J Xia; J-P Allam; L Maintz; T Bieber; N Novak
Journal:  Allergy       Date:  2010-12       Impact factor: 13.146

5.  Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.

Authors:  A Goldberg; R Confino-Cohen
Journal:  J Allergy Clin Immunol       Date:  2001-05       Impact factor: 10.793

6.  IgE to recombinant allergens Api m 1, Ves v 1, and Ves v 5 distinguish double sensitization from crossreaction in venom allergy.

Authors:  U Müller; P Schmid-Grendelmeier; O Hausmann; A Helbling
Journal:  Allergy       Date:  2012-06-08       Impact factor: 13.146

7.  The putative serine protease inhibitor Api m 6 from Apis mellifera venom: recombinant and structural evaluation.

Authors:  Y Michel; M McIntyre; H Ginglinger; M Ollert; L Cifuentes; S Blank; E Spillner
Journal:  J Investig Allergol Clin Immunol       Date:  2012       Impact factor: 4.333

8.  Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom.

Authors:  Joanne N G Oude Elberink; Jan G R De Monchy; Sicco Van Der Heide; Gordon H Guyatt; Anthony E J Dubois
Journal:  J Allergy Clin Immunol       Date:  2002-07       Impact factor: 10.793

9.  Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells.

Authors:  M Pierkes; I Bellinghausen; T Hultsch; G Metz; J Knop; J Saloga
Journal:  J Allergy Clin Immunol       Date:  1999-02       Impact factor: 10.793

10.  Gene expression analysis in allergology: the prediction of Hymenoptera venom allergy severity and treatment efficacy.

Authors:  Marek Niedoszytko; Marta Gruchała-Niedoszytko; Ewa Jassem
Journal:  Clin Transl Allergy       Date:  2013-10-27       Impact factor: 5.871

View more
  6 in total

Review 1.  Quo vadis venomics? A roadmap to neglected venomous invertebrates.

Authors:  Bjoern Marcus von Reumont; Lahcen I Campbell; Ronald A Jenner
Journal:  Toxins (Basel)       Date:  2014-12-19       Impact factor: 4.546

Review 2.  [Insect venom allergies : Update 2016 for otorhinolaryngologists].

Authors:  L Klimek; N Dippold; A Sperl
Journal:  HNO       Date:  2016-12       Impact factor: 1.284

Review 3.  Facing Hymenoptera Venom Allergy: From Natural to Recombinant Allergens.

Authors:  Amilcar Perez-Riverol; Débora Lais Justo-Jacomini; Ricardo de Lima Zollner; Márcia Regina Brochetto-Braga
Journal:  Toxins (Basel)       Date:  2015-07-09       Impact factor: 4.546

Review 4.  Stinging insect allergy: current perspectives on venom immunotherapy.

Authors:  Sian W Ludman; Robert J Boyle
Journal:  J Asthma Allergy       Date:  2015-07-23

5.  VenomKB, a new knowledge base for facilitating the validation of putative venom therapies.

Authors:  Joseph D Romano; Nicholas P Tatonetti
Journal:  Sci Data       Date:  2015-11-24       Impact factor: 6.444

6.  The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow's milk- and peanut allergy models.

Authors:  Marlotte M Vonk; Laura Wagenaar; Raymond H H Pieters; Leon M J Knippels; Linette E M Willemsen; Joost J Smit; Betty C A M van Esch; Johan Garssen
Journal:  Clin Transl Allergy       Date:  2017-09-29       Impact factor: 5.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.